- Home
- ASND vs ELAN Comparison
ASND vs ELAN Comparison
Compare ASND & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | ELAN |
|---|---|---|
| Founded | 2006 | 1954 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.6B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ASND | ELAN |
|---|---|---|
| Price | $225.73 | $22.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $278.80 | $27.63 |
| AVG Volume (30 Days) | 713.8K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,715,000,000.00 |
| Revenue This Year | $98.02 | $7.97 |
| Revenue Next Year | $43.13 | $5.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.22 |
| 52 Week Low | $124.06 | $8.02 |
| 52 Week High | $248.60 | $27.72 |
Technical Indicators
Market Signals| Indicator | ASND | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 37.91 |
| Support Level | $190.49 | $20.41 |
| Resistance Level | $229.94 | $23.70 |
| Average True Range (ATR) | 9.30 | 0.97 |
| MACD | -1.48 | -0.34 |
| Stochastic Oscillator | 21.99 | 8.68 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.